Kevin Reichmuth, MD
Pulmonary Disease · Lincoln, NENPI 1073576229
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $17,480 of the $21,690 with a category attached, or 80.6%. Boehringer Ingelheim accounts for 87.1% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2019 at $7,054 and has fallen 70.6% since, to $2,073 in 2025. Among pulmonary disease clinicians in NE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 67 payments — averaging $323.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$19K
- Inspire Medical Systems, Inc.$2K
- Sunovion Pharmaceuticals Inc.$237
- Jazz Pharmaceuticals Inc.$174
- Philips North America LLC$155
- Regeneron Healthcare Solutions, Inc.$52
- plus $211 from 7 others
Across 130 payments — averaging $1304.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alkermes, Inc.$170K
What the payments were for
- Consulting fees$1,3006%
- Speaking & faculty fees$17,48081%
- Travel & lodging$1,7318%
- Food & beverage$1,0645%
- Education$1151%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 28 | $18,892 |
| Inspire Medical Systems, Inc. | 8 | $1,969 |
| Sunovion Pharmaceuticals Inc. | 14 | $237 |
| Jazz Pharmaceuticals Inc. | 3 | $174 |
| Philips North America LLC | 3 | $155 |
| Regeneron Healthcare Solutions, Inc. | 1 | $52 |
| Resmed Corp | 1 | $48 |
| Grifols USA, LLC | 1 | $41 |
| Insmed, Inc. | 2 | $31 |
| AbbVie | 2 | $29 |
| Novartis | 2 | $27 |
| Sanofi | 1 | $20 |
| Pfizer | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,690 in reported general payments places this provider in the 90th percentile of 81 pulmonary disease providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 133 | $108,527 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 113 | $69,938 |
| Spiriva RespimatTiotropium Bromide | 78 | $48,543 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 65 | $38,163 |
| Breo ElliptaFluticasone/Vilanterol | 58 | $28,955 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 43 | $18,705 |
| SymbicortBudesonide/Formoterol Fumarate | 65 | $18,072 |
| SunosiSolriamfetol Hcl | 11 | $9,720 |
| QuviviqDaridorexant Hcl | 15 | $7,283 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 42 | $5,298 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 170 | $5,239 |
| Modafinil | 37 | $4,317 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 23 | $4,233 |
| Roflumilast | 46 | $3,792 |
| Advair DiskusFluticasone Propion/Salmeterol | 11 | $2,771 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $18,892 | $118,481191 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 81 pulmonary disease providers in Nebraska.
Other pulmonary disease in Lincoln
- Ryan MartinLincoln$600K
- Douglas FiedlerLincoln$23K
- Harvey HopkinsLincoln$18K
- William JohnsonLincoln$18K
- Matthew MaslonkaLincoln$14K
- Jakeb RiggleLincoln$13K
- Jonathan SpencerLincoln$9K
- Louis VioliLincoln$6K
- Jeffrey JarrettLincoln$5K
- Sean BarryLincoln$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.